Clinical trials: Leukemia, Myeloid, Chronic
Chronic Myeloid Leukemia
Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)
The tyrosine kinase inhibitor therapy (iTKs) is the first-line treatment of chronic myelogenous leukemia (CML). Its effectiveness in controlling the progression of the disease is such that it is possible today to consider…
- Trial name
- CAR-LMC (NCT02842320)
- Testing
- biological samples
- Where
- 4 sites in France
- Volunteers
- 53 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Chronic Myelomonocytic Leukemia, Chronic Myelogenous Leukemia
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
This study will evaluate the safety and effectiveness of imatinib (Gleevec(Registered Trademark)) in patients with chronic myelomonocytic leukemia (CMML) and atypical chronic myelogenous leukemia (CML).
- Trial name
- NCT00079313
- Testing
- Imatinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
This phase I/II trial is studying the side effects of biological therapy and to see how well it works in treating patients with advanced myelodysplastic syndrome, chronic myeloid leukemia, acute myeloid leukemia, or acute…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00052520
- Testing
- therapeutic allogeneic lymphocytes, aldesleukin, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Fred Hutchinson Cancer Center
Solid Malignancies, Non-Hodgkin's Lymphoma
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
The purposes of this study are to determine: the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle the side effects of AQ4N when given on the above schedule how much AQ4N is in the…
- Trial name
- NCT00090727
- Testing
- AQ4N
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novacea
Leukemia, Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002766
- Testing
- dactinomycin, sargramostim, carmustine
- Where
- 7 sites in United States
- Volunteers
- 170 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myeloid, Chronic
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
This study will evaluate the efficacy and safety of LBH589B in adult patients with chronic myeloid leukemia who are in accelerated phase or blast phase (blast crisis) with resistant disease following treatment with at least two…
- Trial name
- NCT00449761
- Testing
- LBH589
- Where
- 26 sites in United States, Germany
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
This phase II trial is to see if combining bevacizumab with idarubicin and cytarabine works better in treating patients who have blast phase chronic myelogenous leukemia.
- Trial name
- NCT00023920
- Testing
- bevacizumab, idarubicin, cytarabine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of venetoclax when given together with azacitidine in treating patients with high-risk myelodysplastic syndrome that has come back (recurrent) or does not respond to…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome
- Trial name
- NCT04160052
- Testing
- Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myelomonocytic Leukemia
Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)
Chronic Myelomonocytic Leukemia (CMML) is the most frequent of myelodysplastic/myeloproliferative syndromes, as defined by the WHO classification of myeloid malignancies.
- Trial name
- NCT03280888
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Breast Cancer, Chronic Myeloproliferative Disorders
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
RATIONALE: Probiotics, such as Lactobacillus, may be effective in preventing infections in patients with suppressed immune systems.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00946283
- Testing
- Lactobacillus rhamnosus GG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rutgers, The State University of New Jersey
Leukemia, Lymphoma
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003294
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Chronic Myeloid Leukemia
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
The goal of this clinical research study is to see if a new interferon which is given only once a week with ARA-C works as well as standard interferon and low dose ARA-C. The safety of this treatment will also be studied.
- Trial name
- NCT00303290
- Testing
- Peg Interferon Alpha 2b (Peg Intron), Ara-C (cytosine arabinoside)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- M.D. Anderson Cancer Center
AML, Adult
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML.
- Trial name
- NCT04964518
- Testing
- APG 2575 ramp up arm
- Where
- 9 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Ascentage Pharma Group Inc.
Leukemia, Myelodysplastic Syndromes
Decitabine in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of decitabine in treating patients with myelodysplastic…
- Trial name
- NCT00003361
- Testing
- decitabine
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Lymphoma
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00044954
- Testing
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate
- Where
- 14 sites in United States
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Myeloproliferative Disorders, Fatigue
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
RATIONALE: Giving St. John's wort may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy or hormone therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of St.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00005805
- Testing
- St. John's wort
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Disease, Myelodysplastic Syndromes
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
The purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD).
- Conditions
- Acute Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Myeloproliferative Disorders
- Trial name
- NCT00186342
- Testing
- ablative allogeneic hematopoietic cell transplantation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Chronic Myeloid Leukemia
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.
- Trial name
- NCT02011945
- Testing
- Dasatinib, Nivolumab
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukaemia
Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
The study will study the state of the endothelium in patients with chronic myeloid leukemia during therapy with the II generation tyrosine kinase inhibitor bosutinib.
- Trial name
- NCT05682924
- Testing
- taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
- Where
- 2 sites in Russia
- Volunteers
- 105 people
- Sponsor
- Samara State Medical University
Chronic Myeloid Leukemia
Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy
This was a retrospective, non-interventional, observational cohort study using Optum's de-identified Clinformatics® Data Mart Database.
- Trial name
- ABL-2022-03 (NCT06692803)
- Where
- United States
- Volunteers
- 2,043 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.